Unity Biotechnology (UBX) – Investment Analysts’ Recent Ratings Changes

Share on StockTwits

Several analysts have recently updated their ratings and price targets for Unity Biotechnology (NASDAQ: UBX):

  • 9/9/2020 – Unity Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 9/2/2020 – Unity Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/27/2020 – Unity Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/26/2020 – Unity Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.50 price target on the stock. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/24/2020 – Unity Biotechnology had its “buy” rating reaffirmed by analysts at Mizuho.
  • 8/21/2020 – Unity Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/20/2020 – Unity Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.75 price target on the stock. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/18/2020 – Unity Biotechnology had its price target lowered by analysts at Goldman Sachs Group Inc from $8.00 to $4.00. They now have a “neutral” rating on the stock.
  • 8/18/2020 – Unity Biotechnology was downgraded by analysts at Citigroup Inc from a “buy” rating to a “neutral” rating. They now have a $5.00 price target on the stock, down previously from $31.00.
  • 8/18/2020 – Unity Biotechnology was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $5.00 price target on the stock, down previously from $13.00.
  • 8/17/2020 – Unity Biotechnology was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $4.00 price target on the stock, down previously from $33.00.
  • 8/17/2020 – Unity Biotechnology was downgraded by analysts at Roth Capital from a “buy” rating to a “neutral” rating. They now have a $4.00 price target on the stock, down previously from $35.00.
  • 8/15/2020 – Unity Biotechnology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/14/2020 – Unity Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/7/2020 – Unity Biotechnology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company’s product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. “
  • 8/4/2020 – Unity Biotechnology was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/27/2020 – Unity Biotechnology is now covered by analysts at Roth Capital. They set a “buy” rating and a $35.00 price target on the stock.

Shares of UBX traded up $0.09 during midday trading on Wednesday, reaching $3.62. 35,690 shares of the stock were exchanged, compared to its average volume of 705,504. The company has a market capitalization of $183.70 million, a price-to-earnings ratio of -1.94 and a beta of -0.08. Unity Biotechnology Inc has a twelve month low of $2.72 and a twelve month high of $15.44. The business’s 50-day moving average price is $6.24 and its 200 day moving average price is $6.93.

Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings data on Friday, July 31st. The company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.13. As a group, equities research analysts expect that Unity Biotechnology Inc will post -1.9 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of Unity Biotechnology by 18.2% in the 1st quarter. FMR LLC now owns 4,551,523 shares of the company’s stock worth $36,913,000 after acquiring an additional 700,500 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Unity Biotechnology by 200.1% in the 1st quarter. Russell Investments Group Ltd. now owns 222,585 shares of the company’s stock valued at $1,292,000 after buying an additional 148,424 shares during the period. Asymmetry Capital Management L.P. purchased a new stake in shares of Unity Biotechnology in the second quarter valued at approximately $1,043,000. Bessemer Group Inc. acquired a new position in Unity Biotechnology during the second quarter worth $914,000. Finally, Nuveen Asset Management LLC boosted its holdings in Unity Biotechnology by 45.8% during the second quarter. Nuveen Asset Management LLC now owns 158,880 shares of the company’s stock worth $1,379,000 after buying an additional 49,930 shares in the last quarter. Institutional investors own 47.89% of the company’s stock.

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

See Also: Bollinger Bands

Receive News & Ratings for Unity Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply